Replies to post #267177 on Avid Bioservices Inc (CDMO)

[volgoat]

Nope, and it will be sooner than most think.

Anyone thinks PPHM gives a rats arse about retail investors is delusional.

They will do a massive RS and still keep their jobs and pay.

Any deal possibilities will require a massive RS as no partner is going to pay up and bail out retail investors, ain't gonna happen.


The odds of a deal went down with the Sunset, now there are no trials and no data and a RS soon and not PPHM soon

Then a pipe, BB hopium and wash rinse repeat....

[Protector]

biopharm, This brings us back to PS Receptors vs PS as a molecule (seen as ligand to PS receptor) binding.

More than one group looking to pick up 100% all PS Targeting patents....

Between this post and the related slide



(source) and this slide



(source) several PS receptors were added. We now have the PS receptors on

IMC: MDSC, Macrophages, T-Cell
TIM: Tim1, Tim3, Tim4
TAM: Axl, Mer, Tyro-3
Others: CD300a, RAGE, BAI-1, Stabilin

If Phosphatidylserine gets exposed it will WITHOUT DISCRIMINATION affect and bind ALL above PS receptors at the SAME TIME thereby implementing a global/upstream/systemic strategy to suppress the Immune System from intervening in the Natural Cell Death cycle (apoptosis).

One can immediately see that binding only TIM-1 as does Celldex or TIM-3 as does Novartis, or Axl as does Genentech doesn't implement a GLOBAL approach but just disables ONE specific receptor from binding with PS.

PPHM's Bavituximab and new BetaBodies however CAPS PS itself thereby disabling it from binding with all 12 PS receptors at ones and hence avoid not only suppression by the immune system but also stimulates the immune system to activate (which is a requirement).

Therefor acquiring the patents of PPHM, that cover this broad global approach achieve several things:

- no 12 different drugs needed in I-O combination
- no 12 dosings needed (because all these types of receptors do NOT occur in the same amounts)
- no mine-field of clinical trials to test all these combo's with PD-1, PD-L1, CTLA-4, etc.
- next generation not needing the presence of blood already available
- much higher binding instance because Bavituximab binds the exposed PS on non-mobile cells and reduced amounts in micro vesicles while all others target receptors on immune system cells that move and would have to meet THEIR PS receptor compatible molecule (out of 12) to bind.
- NO T-Cell PS receptor ONLY binding involved (wanted or as side effect (see TIM-3).
- immune system suppression BLOCKING and immune system stimulation at the SAME time
- Immune Response against relapse possible because of that and ONLY because of that.

Additionally other measures are possible. One can try to give transfusions to REMOVE floating PS from the blood stream WITHOUT ANY HARM DONE and so doing lower the amount of PS! One can not do that to the Immune-Cell holding the above mentioned PS Receptors because those cells are NEEDED.

So personally, while I agree that CEO King said that PPHM does not own the complete PS field, I think PPHM holds the patents to the ONLY strategy that can GUARANTEE that a PS molecule, when CAPPED, is disabled for ALL PS receptors at the same time and that wit ONE SINGLE drug to add to a combo.

Furthermore this works for Oncology, Inflamations/Infections, Viral, Surgery/Injury and actually in ALL CASES where a cell exposes PS while NOT due to the natural cell death cycle and where it mistakenly has the side-effect of suppressing the immune system.

PPHM holds all those patents.